/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Kodiak Sciences Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$23.05 0.0436(4.36%) KOD at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 22
Highest Today 23.39
Today’s Open 22
Prev. Close 22
52 Week High 23.63
52 Week Low 1.92
Day’s Range: Low 22 High 23.39
52-Week Range: Low 1.92 High 23.63
1 day return -
1 Week return -0.45
1 month return +27.36
3 month return +167.81
6 month return +475.28
1 year return +214.04
3 year return +215.55
5 year return -81.55
10 year return -

Institutional Holdings

Baker Bros Advisors LP 32.77

BlackRock Inc 6.78

Adage Capital Partners Gp LLC 3.89

Vanguard Group Inc 3.45

ICONIQ Capital, LLC 2.40

TCG Crossover Management, LLC 2.17

Vanguard Total Stock Mkt Idx Inv 2.03

State Street Corp 1.59

Geode Capital Management, LLC 1.50

iShares Russell 2000 ETF 1.49

Renaissance Technologies Corp 1.45

Boxer Capital Management, LLC 1.42

Dimensional Fund Advisors, Inc. 1.38

Board of Ttees Leland Stanford Jr Univ 1.31

D. E. Shaw & Co LP 1.14

Ikarian Capital, LLC 1.14

Nantahala Capital Management, LLC 1.12

BlackRock Advantage Small Cap Core Instl 0.99

Point72 Asset Management, L.P. 0.86

Jacobs Levy Equity Management, Inc. 0.80

SILVERARC CAPITAL MANAGEMENT, LLC 0.76

Northern Trust Corp 0.65

Fidelity Small Cap Index 0.62

Vanguard Institutional Extnd Mkt Idx Tr 0.61

Bruce 0.61

Bruce & Co Inc 0.61

iShares Russell 2000 Value ETF 0.55

Federated Hermes MDT SCC Institutional 0.46

Federated Hermes MDT Small Cap Core IS 0.46

Fidelity Enhanced Small Cap ETF 0.38

Fidelity Extended Market Index 0.33

Vanguard Russell 2000 ETF 0.30

Schwab US Small-Cap ETF™ 0.28

Blackrock Russell 2000 Alpha Tilts Fd A 0.24

State St Russell Sm Cap® Indx SL Cl I 0.23

Goldman Sachs Small Cp Val Insghts Instl 0.22

DFA US Targeted Value I 0.20

DFA US Small Cap I 0.19

Bridgeway Ultra-Small Company Market 0.18

Schwab Small Cap Index 0.16

Market Status

Strong Buy: 1

Buy: 0

Hold: 2

Sell: 3

Strong Sell: 0

Fundamentals

Market Cap 1167.07 M

PB Ratio 49.1255

PE Ratio 0.0

Enterprise Value 1154.05 M

Total Assets 335.58 M

Volume 686035

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-271423000 -271.4M, FY22:339738177000 339738.2M, FY21:-258086000 -258.1M, FY20:-128947000 -128.9M, FY19:-46727000 -46.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-6539000 -6.5M, Q2/2025:-6538000 -6.5M, Q1/2025:-6728000 -6.7M, Q3/2024:null 0.0M, Q2/2024:-6681000 -6.7M

Quarterly Net worth Q3/2025:-61457000 -61.5M, Q2/2025:-54313000 -54.3M, Q1/2025:-57461000 -57.5M, Q3/2024:-43946000 -43.9M, Q2/2024:-45117000 -45.1M

Fund house & investment objective

Company Information Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Organisation Biotechnology

Employees 123

Industry Biotechnology

CEO Dr. Victor Perlroth M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow